Research
Hormonal
GLP-1 receptor agonists (Liraglutide, Semaglutide, Dulaglutide) significantly reduce liver fat content and improve liver enzymes in patients with Type 2 Diabetes and NAFLD, with Semaglutide showing histological resolution of NASH in Phase II trials.
If you have Type 2 Diabetes and NAFLD, ask your doctor about GLP-1 receptor agonists like Semaglutide or Liraglutide. These injectable medications have been shown in clinical trials to reduce liver fat and improve liver inflammation, in addition to helping with weight and blood sugar control.
GoodSupportsHIGH confidence
Liraglutide... can improve IR and reduce LFC in T2DM patients... A Phase II clinical trial showed that the subcutaneous injection of liraglutide at a dose of 1.8 mg/d in NASH patients could improve the histopathology of the liver... semaglutide... NSAH in the experimental group was relieved... optimal injection concentration... was 0.4 mg/d
Why this rating
Supported by multiple Phase II trials and meta-analyses, though long-term Phase III data is still being validated.
Source
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
Rong Li et al. · Frontiers in Endocrinology · 2023
DOI 10.3389/fendo.2022.1087260
narrative_reviewCited 283×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Lifestyle interventions, specifically caloric restriction and exercise, are the foundational first-line treatment for NAFLD, capable of inducing 5-10% weight loss and improving insulin resistance and hepatic steatosis.Good
- SGLT2 inhibitors (Empagliflozin, Dapagliflozin, Ipragliflozin) improve liver fat content and liver enzymes in patients with Type 2 Diabetes and NAFLD, with some evidence of improving liver fibrosis.Good
- Bariatric surgery is an effective treatment for severe obesity in adolescents and adults with NAFLD, significantly improving liver histology, fibrosis, and metabolic parameters, but carries risks of complications.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →